La vendita allo scoperto per Insmed dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Insmed. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Insmed (NASDAQ:INSM) Azioni, Report sulle vendite allo scoperto

Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Inc

Throughout the last three months, 7 analysts have evaluated Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.71, a high estimate of $105.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 5.54% increase from the previous average price target of $85.00.
<img src="https://www.benzinga.com/files/images/story/2024/1732287652_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Insmed. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Insmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Insmed's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h2>About Insmed</h2>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
<h3>A Deep Dive into Insmed's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Insmed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insmed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -236.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -84.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.42%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.07.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INSM

Demystifying Insmed: Insights From 7 Analyst Reviews

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $74 to $83.

News

Price Target

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $83

U.S. stocks were lower, with the Dow Jones index falling more than 350 points on Tuesday.
Shares of Energizer Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/ENR/earnings">better-than-expected quarterly earnings.</a>
Energizer reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.17 per share. The company reported quarterly sales of $805.70 million which missed the analyst consensus estimate of $806.4 million.
Energizer shares jumped 12.8% to $38.52 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares jumped 31.9% to $28.41 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) gained 26.5% to $38.66 after the company on Monday reported better-than-expected quarterly financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares rose 17% to $2.0600.</li>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares jumped 16.2% to $10.04.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) surged 15.4% to $30.20.</li>
<li>C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares rose 14.3% to $30.33 after the company announced a strategic alliance with Microsoft to accelerate the adoption of enterprise AI on Azure.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) surged 12.7% to $38.93</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 11.6% to $8.65.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) gained 11.5% to $17.82.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 10% to $12.84.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) surged 7.7% to $71.73. Insmed, on Nov. 18, terminated sales agreement with Leerink Partners.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares rose 7.1% to $6.01. Needham analyst Chris Pierce initiated coverage on Joby Aviation with a Buy rating and announced a price target of $8.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 5.5% to $21.83.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42060660/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

ALMS

APLD

APLS

BBAI

JOBY

LMND

LUNR

OKLO

OSCR

SMCI

Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday

Insmed On Nov. 18 Terminated Sales Agreement With Leerink Partners

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) revealed 13 unusual trades.
Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $855,036, and 3 were calls, valued at $419,310.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $85.0 for Insmed over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.
<h3>Insmed Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731961828_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.2</td>
<td>$0.75</td>
<td>$1.2</td>
<td>$85.00</td>
<td>$360.0K</td>
<td>7.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.1</td>
<td>$3.8</td>
<td>$4.06</td>
<td>$62.50</td>
<td>$150.3K</td>
<td>504</td>
<td>2.3K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.5</td>
<td>$3.4</td>
<td>$3.9</td>
<td>$62.50</td>
<td>$142.3K</td>
<td>504</td>
<td>365</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$138.4K</td>
<td>504</td>
<td>1.5K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$123.2K</td>
<td>504</td>
<td>746</td>
</tr>
</tbody>
</table>

<h3>About Insmed</h3>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Insmed Standing Right Now?</h3>
<ul>
<li>With a trading volume of 891,951, the price of INSM is down by -0.03%, reaching $66.27.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Insmed</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $97.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $105. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $90.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Insmed options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Insmed's Options: A Look at What the Big Money is Thinking

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Nov. 8:
Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>): The biopharmaceutical company saw increased interest from investors over the week, which comes after the company <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update">reported </a>third-quarter financial results and provided a company update in late October. The company said ARIKAYCE had revenue of $93.4 million in the quarter, up 18% year-over-year. 
Insmed also said its NDA submission for Brensocatib in Bronchiectasis is on track for the fourth quarter and is expected to launch in the U.S. in mid-2025. 
H.C. Wainwright reiterated a Buy rating and $90 price target on the stock <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">after the quarterly results</a>. Truist reiterated a Buy rating and raised the price target from $100 to $105. Investor interest could increase in the coming weeks with the company scheduled to participate in several conferences including ones from Guggenheim (Nov. 11), UBS Global (Nov. 12), Wolfe Research (Nov. 20) and Jefferies (Nov. 21).
Insmed shares were up over 8% in the last five trading days, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 140% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png" alt="" class="wp-image-638350" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-768x389.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Applied Industrial Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>): The industrial company was one of several in the sector to see strong interest from readers, which could be related to Donald Trump winning<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> the 2024 election.</a> Industrials were a top performing sector under <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">Trump&#8217;s previous four years</a> in the White House. 
The company also recently <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx">reported </a>first-quarter financial results with earnings per share of $2.36 and revenue of $1.10 billion, beating Street consensus estimates of $2.27 and $1.09 billion respectively. Applied Industrial also increased its fiscal 2025 earnings per share guidance to a range of $9.25 to $10.00, up from prior guidance of $9.20 to $9.95 and ahead of a Street estimate of $9.39. 
Analysts <a href="https://www.benzinga.com/quote/AIT/analyst-ratings">raised their price targets</a> on the stock after the quarterly results. The stock was up over 15% in the last five trading days and is up over 50% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png" alt="" class="wp-image-638351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>): The specialty grocery retailer saw strong interest from Benzinga readers during the week, which comes after <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx">recent </a>quarterly results and with shares trading at 52-week highs. The company's third-quarter earnings per share of 91 cents and revenue of $1.90 billion beat Street estimates of 76 cents per share and $1.88 billion respectively.
The company said the third quarter was exceptional and CEO Jack Sinclair highlighted "robust traffic growth." Same store sales were up 8.4% in the third quarter. The company opened nine new stores, ending the quarter with 428 stores in 23 states. 
Goldman Sachs recently <a href="https://www.benzinga.com/quote/SFM/analyst-ratings">maintained a Buy rating </a>on the stock and raised the price target from $127 to $159. Wells Fargo maintained an Equal-Weight rating on the stock and raised the price target from $90 to $130. 
The stock was up over 10% over the last five trading days, and shares are up over 190% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png" alt="" class="wp-image-638353" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): The medical devices company saw strong interest from readers over the last week, with shares trading at 52-week highs Friday. 
The company recently reported <a href="https://www.benzinga.com/news/earnings/24/10/41391471/intuitive-surgical-stock-pops-on-q3-earnings-beat-da-vinci-procedures-climb-18-regulatory-clearance">third-quarter financial results </a>with revenue of $2.04 billion beating a Street consensus estimate of $2.0 billion and earnings per share of $1.84 beating a Street consensus estimate of $1.63. Intuitive Surgical reported revenue growth of 17% year-over-year in the quarter, with worldwide da Vinci procedures up 18% year-over-year. 
The company also placed 379 da Vinci systems in the quarter, up from 312 in the prior quarter. There are 9,539 installed da Vinci surgical systems as of the end of the quarter. Intuitive obtained regulatory clearance for the da Vinci 5 surgical system in South Korea in October. 
The earnings report saw several<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt"> analysts raise their price targets </a>on the stock. Analysts see the company's updated da Vinci 5 system, which can be used for more types of surgeries as a growth catalyst moving forward. Shares of Intuitive Surgical were up around six percent in the last five days and are up over 60% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png" alt="" class="wp-image-638354" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>): The industrials company was another in the sector that saw increased interest and a soaring stock price, potential from Trump's 2024 election win. The company recently <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings">reported </a>third-quarter net sales of $997.8 million, beating a Street consensus estimate of $936.0 million and quarterly earnings per share of $1.48, which beat a Street estimate of $1.32. Mueller Industries said the revenue growth came from recently acquired businesses and higher copper prices in the quarter.
"We anticipated that declining interest rates and moderating inflation, combined with the resolution of election related uncertainty, will create a more stable and favorable environment for us," Mueller CEO Greg Christopher said.
The stock was up 13% over the last five days and is up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png" alt="" class="wp-image-638355" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">November 1</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>
Photo: Benzinga

Exclusives

ISRG

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Truist Securities analyst Nicole Germino reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $100 to $105.

Reiteration

Truist Securities Reiterates Buy on Insmed, Raises Price Target to $105

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Biotech

Earnings

Guidance

Health Care

General

Insmed Reiterates Its Guidance For Full-year 2024 Global Arikayce Revenues Of $340M-$360M

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.21) by 4.96 percent. The company reported quarterly sales of $93.42 million which beat the analyst consensus estimate of $93.01 million by 0.44 percent. This is a 18.15 percent increase over sales of $79.07 million the same period last year.

Insmed Q3 2024 GAAP EPS $(1.27) Misses $(1.21) Estimate, Sales $93.42M Beat $93.01M Estimate

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Insmed will report an earnings per share (EPS) of $-1.21.
Investors in Insmed are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.67, which was followed by a 3.02% increase in the share price the next day.
Here's a look at Insmed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.27</td>
<td>-1.23</td>
<td>-1.15</td>
<td>-1.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.94</td>
<td>-1.06</td>
<td>-1.28</td>
<td>-1.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730297050_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/INSM/earnings">To track all earnings releases for Insmed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Insmed's Earnings Potential

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.11% on an annualized basis producing an average annual return of 17.42%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $4,953.54 today based on a price of $71.52 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729874375_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 8.04% since its last report. The company recently reported that it has 13.20 million shares sold short, which is 7.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729786627_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.08%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Insmed's Recent Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.97% on an annualized basis producing an average annual return of 18.54%. Currently, Insmed has a market capitalization of $12.83 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $552.22 today based on a price of $74.66 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729026018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $85 to $100.

Truist Securities Maintains Buy on Insmed, Raises Price Target to $100

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $84 to $86.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $86

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $72 to $74.

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $74

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.39% on an annualized basis producing an average annual return of 18.6%. Currently, Insmed has a market capitalization of $12.71 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $561.05 today based on a price of $73.95 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726851688_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years

Looking for broad exposure to the Small Cap Value segment of the US equity market? You should consider the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (ARCA:BBSC), a passively managed exchange traded fund launched on 11/16/2020.
The fund is sponsored by J.P. Morgan. It has amassed assets over $520.35 million, making it one of the average sized ETFs attempting to match the Small Cap Value segment of the US equity market.
<h2>Why Small Cap Value</h2>
Small cap companies have market capitalization below $2 billion. They usually have higher potential than large and mid cap companies with stocks but higher risk.
While value stocks have lower than average price-to-earnings and price-to-book ratios, they also have lower than average sales and earnings growth rates. Value stocks have outperformed growth stocks in nearly all markets when you consider long-term performance, growth stocks are more likely to outpace value stocks in strong bull markets.
<h2>Costs</h2>
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF&#39;s expense ratio.
Annual operating expenses for this ETF are 0.09%, making it one of the least expensive products in the space.
It has a 12-month trailing dividend yield of 1.48%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund&#39;s holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Financials sector--about 19.90% of the portfolio. Healthcare and Industrials round out the top three.
Looking at individual holdings, Jpmorgan Us Govt Mmkt Fun accounts for about 1.50% of total assets, followed by Insmed Inc Common Stock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insm#NASDAQ">INSM</a>) and Carpenter Technology (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>).
The top 10 holdings account for about 5.66% of total assets under management.
<h2>Performance and Risk</h2>
BBSC seeks to match the performance of the MORNINGSTAR US SML CP TRG MRK EXP EXT ID before fees and expenses. The Morningstar US Small Cap Target Market Exposure Extended Index is a free-float adjusted, market-cap weighted index that targets small cap securities traded in the U.S.
The ETF has gained about 7.42% so far this year and it&#39;s up approximately 20.46% in the last one year (as of 09/16/2024). In the past 52-week period, it has traded between $48.58 and $67.50.
The ETF has a beta of 1.08 and standard deviation of 23.45% for the trailing three-year period. With about 796 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
JPMorgan BetaBuilders U.S. Small Cap Equity ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, BBSC is an excellent option for investors seeking exposure to the Style Box - Small Cap Value segment of the market. There are other additional ETFs in the space that investors could consider as well.
The Avantis U.S. Small Cap Value ETF (ARCA:AVUV) and the Vanguard Small-Cap Value ETF (ARCA:VBR) track a similar index. While Avantis U.S. Small Cap Value ETF has $12.95 billion in assets, Vanguard Small-Cap Value ETF has $29.58 billion. AVUV has an expense ratio of 0.25% and VBR charges 0.07%.
<h2>Bottom-Line</h2>
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
<a href="https://www.zacks.com/stock/news/2336240/should-jpmorgan-betabuilders-u-s-small-cap-equity-etf-bbsc-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-2336240">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Sector ETFs

Dividends

Small Cap

ETFs

AVUV

BBSC

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF Be on Your Investing Radar?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Regeneron (REGN ...

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)

Truist Financial analyst Nicole Germino maintained a Buy rating on Insmed (INSM – Research Report) yesterday and set a price target of $105.00. The...

Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)

Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidates - BofA

Insmed gains after ending $500M sales pact with Leerink

Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and more

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on INSM stock, giving a Buy rating on November 8. Joseph Schwartz's ra...

Insmed's Strategic Growth and Market Potential Drive Buy Recommendation

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Insmed (INSM – Research Report) yesterday and set a price target of $9...

Insmed's Strategic Advancements and Promising Pipeline Justify Buy Rating

Franklin Convertible Securities Fund Q3 2024 Commentary

JPMorgan raised the firm's price target on Insmed (INSM) to $83 from $74 and keeps an Overweight rating on the shares. The firm updated the company...

Insmed price target raised to $83 from $74 at JPMorgan

AAPL

ALIT

ALKS

AMZN

ANSS

APEI

APOG

APTV

ARGX

ATKR

AVGO

AXON

BABA

BABAF

BKNG

BURL

COLL

CORZ

CPNG

CVNA

CWCO

DXCM

EXPE

FFIV

FLUT

FLYW

FOLD

GOOGL

GWRE

HALO

HSII

HUBS

IVPAF

JNPR

LBRDK

LNTH

LUNG

MELI

MKSI

MSFT

NFLX

NTRA

NVDA

OTTR

PLAB

PODD

PRCT

PTON

PYPL

REGN

REXR

RXST

SMAR

SNAP

SPOT

STNG

TEVA

UBER

WELL

WOLF

Press Releases

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

Comments

Insmed

Vendite allo scoperto

Insmed (NASDAQ:INSM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO